|
Canada-0-Musicians ไดเรกทอรีที่ บริษัท
|
ข่าว บริษัท :
- Bempedoic Acid and Cardiovascular Outcomes in Statin . . .
The risk of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (the first key secondary end point) was 15% lower with bempedoic acid than with placebo, and the
- U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
U S FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
- Nexletol shows CLEAR benefit in cardiovascular outcome trial
New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout
- Evaluation of Major Cardiovascular Events in Participants . . .
The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant
- U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
- Esperion Showcases New Data from CLEAR Outcomes Highlighting . . .
“These new analyses from CLEAR Outcomes further strengthen the evidence base supporting NEXLETOL as a proven therapy for cardiovascular risk reduction - especially for patients who cannot tolerate statin therapy,” said Sheldon Koenig, President and Chief Executive Officer of Esperion
- U. S. FDA Approves Broad New Labels for Esperion’s NEXLETOL . . .
Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary
- Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase . . .
Bempedoic acid is a new drug that improves the control of cholesterol levels, either as monotherapy or in combination with existing lipid-lowering therapies, and shows clinical efficacy in cardiovascular disease patients Thus, patients with
- Nexletol: Uses, Dosage, Side Effects, Warnings - Drugs. com
Nexletol (bempedoic acid) is an oral tablet for high cholesterol that may be used to lower the risk of heart attack and heart procedures (for example stent placement or bypass surgery), in adults not taking a statin who have known heart disease or are at
- U. S. FDA Approves Broad New Labels for NEXLETOL and . . . - DAIC
April 1, 2024 — Esperion announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention
|
|